EP1680119A1 — 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
Assigned to Wyeth LLC · Expires 2006-07-19 · 20y expired
What this patent protects
Compounds of formula (I) wherein n is an integer from 1-3; X is N, CH, provided that when X is N, n is 2 or 3; R is alkyl of 1 to 3 carbon atoms; R1 is 2,4-diCI, 5-OMe; 2,4-diCI; 3,4,5-triOMe; 3-CI, 5-OMe; 2-Me, 5-OMe; 2,4-di-Me; 2,4-diMe-5-OMe, 2,4-diCI, 5-OEt; R2 is alkyl of 1 …
USPTO Abstract
Compounds of formula (I) wherein n is an integer from 1-3; X is N, CH, provided that when X is N, n is 2 or 3; R is alkyl of 1 to 3 carbon atoms; R1 is 2,4-diCI, 5-OMe; 2,4-diCI; 3,4,5-triOMe; 3-CI, 5-OMe; 2-Me, 5-OMe; 2,4-di-Me; 2,4-diMe-5-OMe, 2,4-diCI, 5-OEt; R2 is alkyl of 1 to 2 carbon atoms, and pharmaceutically acceptable salts thereof are useful for the treatment of chronic myelogenous leukemia (CML).
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.